Navigation Links
Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show

NEW YORK, May 28 /PRNewswire/ -- The UltraPulse CO2 fractional laser was featured today on NBC's Today Show as an exciting and revolutionary new treatment for scars. During the broadcast, triplets who were severely burned in a fire as infants told their personal story and discussed recent treatments with the Lumenis UltraPulse laser. After only two treatments with the groundbreaking ActiveFX and DeepFX technologies, the triplets Jordan, Trae and Chandra Berns have achieved noticeable improvement in the appearance of their scars. The triplets' incredible story was also featured in the May issue of Glamour.

Dr. Kenneth Beer and Dr. Jill Waibel, the West Palm Beach physicians treating the triplets, are pioneers in the application of fractional lasers for the treatment of scars. They chose the Lumenis' UltraPulse system due to its dual-treatment modality.

"My objective when treating scars is two-fold: first, I ablate away portions of the scar by drilling micro-channels deep into the affected area, thereby eliminating part of the scar and enabling increased mobility and improved appearance. This treatment is known as DeepFX, and it serves to create new healthy tissue replacing the bulky scar tissue. Then, I use the ActiveFX treatment on the surface of the skin to smooth and even out the texture as well as remove any discoloration and unwanted pigmentation," explained Dr. Waibel. "This dual-treatment regimen is known as TotalFX, and it offers a unique inside out approach that can be applied to treating all scars including burn scars, acne scars, and traumatic injury scars."

"Dr. Beer and Dr. Waibel contacted Lumenis after the Berns sisters came to their Palm Beach office for a consultation. The doctors felt that the UltraPulse laser would be the ideal treatment choice for the triplets. Lumenis was very happy to support the extensive treatments that the Berns sisters required. We will continue to support innovative work treating traumatic scars with the UltraPulse system," added Robert Mann, General Manager Global Aesthetics and Dermatology at Lumenis.

Lumenis pioneered skin resurfacing over 18 years ago with its C02 lasers. The Lumenis UltraPulse laser system has FDA clearance for more than 34 indications and is referenced in excess of 90 peer-reviewed publications. Although frequently used for aesthetic applications, the UltraPulse offers 240 watts of power and microsecond pulses which combined provide a broad canvas from which other treatments in cutaneous surgical and aesthetic applications can be provided.

"With its Aesthetic, Surgical and Ophthalmic divisions, Lumenis has the unique advantage to offer physicians novel applications to bridge the gap between surgical and aesthetic treatments," commented Dov Ofer, CEO of Lumenis. "Dealing with burn scars is an excellent example of how a premium laser such as our UltraPulse system, when used extensively in surgical and aesthetic applications in the hands of leading physicians, can drive new treatments and offer hope to people around the world."

The entire story of the Berns triplets and their treatments using the UltraPulse Fractional CO2 laser can be found at

About Lumenis

Lumenis is Israel's largest medical device company with more than 800 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, presence in over 100 countries worldwide, and an installed base of over 70,000 systems. For more information about Lumenis and its products, log onto

Lumenis(R) is a registered trademark of Lumenis Ltd. UltraPulse(R) is a trademark of Lumenis Ltd.

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled "Risk Factors", as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.

    Contacts:    Charly Rok
                 Lippe Taylor
                 Office: 212-598-4400 x155
                 Cell:  917-912-2863

                 Michelle Maydan
                 Director of Corporate Communications
                 Toll-free: 1-866-569-0597
                 Office: +972-4-959-9004

SOURCE Lumenis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nosespray vaccine using aloe vera has exciting potential, researcher says
2. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists
3. 3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI
4. Leicester scientist announces unexpected and exciting advance in study of cancer type
5. WRAIR investigators pioneering work on an exciting new class of antimalarial compounds
6. Cholera study provides exciting new way of looking at infectious disease
7. Reflex Stock Launches Exciting New Editorial Image Collections to the Worldwide Publishing Industry
8. New NAMC Member Service! Complimentary Webinars for NAMC Members - On Topics You Need to Know! Sign Up Today for This New and Exciting Educational Program!
9. Exciting discovery could stop cancer from killing people
10. HotHead Technologies Heat Sensor Shows Exciting Potential by Kennesaw State University Researchers
11. Scientists eavesdrop on the exciting conversations within cells
Post Your Comments:
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology: